{"id":23976,"date":"2022-11-30T11:58:00","date_gmt":"2022-11-30T03:58:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23976"},"modified":"2025-01-30T12:03:29","modified_gmt":"2025-01-30T04:03:29","slug":"zhejiang-jiuzhou-pharma-to-raise-rmb-2-5-billion-via-private-placement","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23976","title":{"rendered":"Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement"},"content":{"rendered":"\n

China-based Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456<\/a>) has received approval from the China Securities Regulatory Commission (CSRC) to conduct a private placement of 70 million shares. The company plans to raise RMB 2.5 billion (USD 350 million) through this transaction, with proceeds allocated towards the Phase 1 construction of a contract development and manufacturing organization (CDMO) base in Taizhou, raw material CDMO construction in Suzhou, and supplementary working capital.<\/p>\n\n\n\n

Company Background<\/strong>
Founded in 1998, Jiuzhou Pharma is a leading provider of one-stop, high-quality services spanning the entire pharmaceutical industry chain, from pre-clinical CMC, clinical trials, and NDA to product listing. The company operates research and development (R&D) centers in Hangzhou and Taizhou in Zhejiang Province, Nanjing in Jiangsu Province, and North Carolina in the United States. Additionally, Jiuzhou Pharma has manufacturing bases in Zhejiang and Jiangsu provinces, supporting its comprehensive service offerings.<\/p>\n\n\n\n

Expansion Plans<\/strong>
The funds raised through the private placement will significantly bolster Jiuzhou Pharma\u2019s CDMO capabilities, enhancing its position as a key player in the global pharmaceutical market. The expansion projects in Taizhou and Suzhou are expected to boost the company\u2019s production capacity and efficiency, while the additional working capital will support ongoing operations and strategic initiatives.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456) has received approval from the China Securities…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[19,20,646,1331],"class_list":["post-23976","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cro-cmo-cdmo","tag-finance","tag-jiuzhou-pharmaceutical","tag-sha-603456"],"yoast_head":"\nZhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456) has received approval from the China Securities Regulatory Commission (CSRC) to conduct a private placement of 70 million shares. The company plans to raise RMB 2.5 billion (USD 350 million) through this transaction, with proceeds allocated towards the Phase 1 construction of a contract development and manufacturing organization (CDMO) base in Taizhou, raw material CDMO construction in Suzhou, and supplementary working capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23976\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23976\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-30T03:58:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-30T04:03:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23976#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23976\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement\",\"datePublished\":\"2022-11-30T03:58:00+00:00\",\"dateModified\":\"2025-01-30T04:03:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23976\"},\"wordCount\":212,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"Finance\",\"Jiuzhou Pharmaceutical\",\"SHA: 603456\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23976#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23976\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23976\",\"name\":\"Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-11-30T03:58:00+00:00\",\"dateModified\":\"2025-01-30T04:03:29+00:00\",\"description\":\"China-based Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456) has received approval from the China Securities Regulatory Commission (CSRC) to conduct a private placement of 70 million shares. The company plans to raise RMB 2.5 billion (USD 350 million) through this transaction, with proceeds allocated towards the Phase 1 construction of a contract development and manufacturing organization (CDMO) base in Taizhou, raw material CDMO construction in Suzhou, and supplementary working capital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23976#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23976\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23976#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement - Insight, China's Pharmaceutical Industry","description":"China-based Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456) has received approval from the China Securities Regulatory Commission (CSRC) to conduct a private placement of 70 million shares. The company plans to raise RMB 2.5 billion (USD 350 million) through this transaction, with proceeds allocated towards the Phase 1 construction of a contract development and manufacturing organization (CDMO) base in Taizhou, raw material CDMO construction in Suzhou, and supplementary working capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23976","og_locale":"en_US","og_type":"article","og_title":"Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23976","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-11-30T03:58:00+00:00","article_modified_time":"2025-01-30T04:03:29+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23976#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23976"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement","datePublished":"2022-11-30T03:58:00+00:00","dateModified":"2025-01-30T04:03:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23976"},"wordCount":212,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CRO \/ CMO \/ CDMO","Finance","Jiuzhou Pharmaceutical","SHA: 603456"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23976#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23976","url":"https:\/\/flcube.com\/?p=23976","name":"Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-11-30T03:58:00+00:00","dateModified":"2025-01-30T04:03:29+00:00","description":"China-based Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456) has received approval from the China Securities Regulatory Commission (CSRC) to conduct a private placement of 70 million shares. The company plans to raise RMB 2.5 billion (USD 350 million) through this transaction, with proceeds allocated towards the Phase 1 construction of a contract development and manufacturing organization (CDMO) base in Taizhou, raw material CDMO construction in Suzhou, and supplementary working capital.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23976#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23976"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23976#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23976"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23976\/revisions"}],"predecessor-version":[{"id":23977,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23976\/revisions\/23977"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}